Prognostic value of Ki67 index in anaplastic oligodendroglial tumours - a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group

Histopathology

Volumn 60, Issue 6, 2012, Pages 885-894

  Preusser, Matthias ^a   Hoeftberger, Romana ^b   Woehrer, Adelheid ^a,b   Gelpi, Ellen ^b   Kouwenhoven, Mathilde ^c   Kros, Johan M ^c   Sanson, Marc ^d   Idbaih, Ahmed ^d   Brandes, Alba A ^e   Heinzl, Harald ^a   Gorlia, Thierry ^f   Hainfellner, Johannes A ^a,b   van den Bent, Martin ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d INSERM   (France)

^e Azienda USL di Bologna   (Italy)

^f EORTC DATA CENTER   (Belgium)

Author keywords

Ki67; Oligodendroglial tumour; Prognosis

Indexed keywords

DNA METHYLTRANSFERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; FORMALDEHYDE; ISOCITRATE DEHYDROGENASE; KI 67 ANTIGEN; PARAFFIN;

ADULT; ANAPLASTIC OLIGODENDROGLIAL TUMOR; ARTICLE; CANCER DIAGNOSIS; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE AMPLIFICATION; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL;

AGED; BRAIN NEOPLASMS; EUROPE; HUMANS; KI-67 ANTIGEN; OBSERVER VARIATION; OLIGODENDROGLIOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SURVIVAL RATE; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84860283371     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04134.x     Document Type: Article

References (26)

1. Louis DN, Ohgaki H, Wiestler OD, Cavanee WK. WHO classification of tumours of the central nervous system, 4th edn. Lyon: IARC Press, 2007.
2. Bromberg JE, van den Bent MJ. Oligodendrogliomas: molecular biology and treatment. Oncologist 2009; 14; 155-163.
3. Brandes AA, Tosoni A, Cavallo G et al. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J. Clin. Oncol. 2006; 24; 4746-4753.
4. van den Bent MJ, Dubbink HJ, Marie Y et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 2010; 16; 1597-1604.
5. van den Bent MJ, Dubbink HJ, Sanson M et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. J. Clin. Oncol. 2009; 27; 5881-5886.
6. Kouwenhoven MC, Gorlia T, Kros JM et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro. Oncol. 2009; 11; 737-746.
7. Ramirez C, Bowman C, Maurage CA et al. Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors - towards individualized tumor treatment? Neuro. Oncol. 2010; 12; 490-499.
8. Cairncross JG, Ueki K, Zlatescu MC et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 1998; 90; 1473-1479.
9. Kros JM, Hop WC, Godschalk JJ, Krishnadath KK. Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer 1996; 78; 1107-1113.
10. Coons SW, Johnson PC, Pearl DK. The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery 1997; 41; 878-884; discussion 884-875.
11. Prayson RA, Mohan DS, Song P, Suh JH. Clinicopathologic study of forty-four histologically pure supratentorial oligodendrogliomas. Ann. Diagn. Pathol. 2000; 4; 218-227.
12. Coleman KE, Brat DJ, Cotsonis GA, Lawson D, Cohen C. Proliferation (MIB-1 expression) in oligodendrogliomas: assessment of quantitative methods and prognostic significance. Appl. Immunohistochem. Mol. Morphol. 2006; 14; 109-114.
13. Heegaard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer 1995; 76; 1809-1813.
14. van den Bent MJ, Carpentier AF, Brandes AA et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 2006; 24; 2715-2722.
15. van den Bent MJ. Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective. Acta Neuropathol. 2010; 120; 297-304.
16. Kros JM, Gorlia T, Kouwenhoven MC et al. Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J. Neuropathol. Exp. Neurol. 2007; 66; 545-551.
17. Idbaih A, Dalmasso C, Kouwenhoven M et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. J. Neurooncol. 2010; 103; 221-230.
18. Preusser M, Heinzl H, Gelpi E et al. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 2008; 53; 39-47.
19. Wolfsberger S, Fischer I, Hoftberger R et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am. J. Surg. Pathol. 2004; 28; 914-920.
20. Jeuken JW, Cornelissen SJ, Vriezen M et al. MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab. Invest. 2007; 87; 1055-1065.
21. Lin LI. A concordance correlation coefficient to evaluate reproducibility. Biometrics 1989; 45; 255-268.
22. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy and reducing errors. Stat. Med. 1996; 15; 361-387.
23. Sauerbrei W, Schumacher M. A bootstrap resampling procedure for model building: application to the Cox regression model. Stat. Med. 1992; 11; 2093-2109.
24. Prayson RA, Castilla EA, Hembury TA, Liu W, Noga CM, Prok AL. Interobserver variability in determining MIB-1 labeling indices in oligodendrogliomas. Ann. Diagn. Pathol. 2003; 7; 9-13.
25. Hsu CY, Ho DM, Yang CF, Chiang H. Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod. Pathol. 2003; 16; 951-957.
26. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J. Pathol. 2002; 198; 292-299.